Cost-effectiveness of the prophylactic HPV vaccine: An application to the Netherlands taking non-cervical cancers and cross-protection into account

Vaccine

Volumn 31, Issue 37, 2013, Pages 3922-3927

  Luttjeboer, J ^a   Westra, T A ^a,b   Wilschut, J C ^b   Nijman, H W ^b   Daemen, T ^b   Postma, M J ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cost effectiveness analysis; Cross protection; HPV; Non cervical cancers

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; CROSS PROTECTION; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; VACCINATION;

COST-EFFECTIVENESS ANALYSIS; CROSS-PROTECTION; HPV; NON-CERVICAL CANCERS;

ANUS NEOPLASMS; CHILD; COST-BENEFIT ANALYSIS; CROSS PROTECTION; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNIZATION PROGRAMS; MODELS, ECONOMIC; NETHERLANDS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 84881544412     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.044     Document Type: Article

References (26)

1. Rogoza R.M., Westra T.A., Ferko N., Tamminga J.J., Drummond M.F., Daemen T., et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009, 27(July (35)):4776-4783.
2. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(August (Suppl. 3)):S11-S25.
3. Lowy D.R., Schiller J.T. Reducing HPV-associated cancer globally. Cancer Prev Res (Phila) 2012, 5(January (1)):18-23.
4. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359(August (8)):821-832.
5. Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., Perez G., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2(October (10)):868-878.
6. GlaxoSmithKline. Cervarix summary of product characteristics. Available from: http://www.medicines.org.uk/emc/medicine/20204/SPC/cervarix/.
7. Causes of death; main primary causes of death, sex, age. Available from: http://www.statline.cbs.nl/.
8. Dutch cancer Figures. Available from: http://cijfersoverkanker.nl/?language=en.
9. Chesson H.W., Ekwueme D.U., Saraiya M., Dunne E.F., Markowitz L.E. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29(October (46)):8443-8450.
10. De Vuyst H., Clifford G.M., Nascimento M.C., Madeleine M.M., Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 1(April (7)):1626-1636.
11. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011, 15(February (4)):927-935.
12. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14(February (2)):467-475.
13. Brigg A., Claxton K., Sculpher M. Decision modelling for health economic evaluation 2006, Oxford University Press, New York.
14. Ricciardi A., Largeron N., Giorgi Rossi P., Raffaele M., Cohet C., Federici A., et al. Incidence of invasive cervical cancer and direct costs associated with its management in Italy. Tumori 2009, 95(April (2)):146-152.
15. De Kok I.M., Habbema J.D., van Rosmalen J., van Ballegooijen M. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness. Eur J Cancer 2011, 47(February (3)):428-435.
16. Uyl-De Groot C.A., Hartog J.G., Derksen J.G., Symons E.A., Buijt I., van der Velden J., et al. Cost-effectiveness and quality of life of granulocyte-colony stimulating factor (filgrastim) after radical vulvectomy and bilateral inguino-femoral lymphadenectomy: results of a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2004, 114(May (1)):77-82.
17. Polder J.J., Barendregt J.J., van Oers H. Health care costs in the last year of life-the Dutch experience. Soc Sci Med 2006, 63(October (7)):1720-1731.
18. Wilschut J.A., Hol L., Dekker E., Jansen J.B., Van Leerdam M.E., Lansdorp-Vogelaar I., et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011, 141(November (5)). 1648-55.e1.
19. Elferink M.A., Pukkala E., Klaase J.M., Siesling S. Spatial variation in stage distribution in colorectal cancer in the Netherlands. Eur J Cancer 2012, 48(May (8)):1119-1125.
20. Lansdorp-Vogelaar I., van Ballegooijen M., Zauber A.G., Habbema J.D., Kuipers E.J. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009, 101(October (20)):1412-1422.
21. van Agthoven M., van Ineveld B.M., de Boer M.F., Leemans C.R., Knegt P.P., Snow G.B., et al. The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer 2001, 37(November (17)):2204-2211.
22. Chesson H.W., Ekwueme D.U., Saraiya M., Markowitz L.E. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008, 14(February (2)):244-251.
23. Sun C.C., Frumovitz M., Bodurka D.C. Quality of life and gynecologic malignancies. Curr Oncol Rep 2005, 7(November (6)):459-465.
24. Bogaards J.A., Coupe V.M., Meijer C.J., Berkhof J. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine 2011, 29(November (48)):8929-8936.
25. Harper D.M., Vierthaler S.L. Next generation cancer protection: the bivalent HPV vaccine for females. ISRN Obstet Gynecol 2011, (July).
26. De Kok I.M., van Ballegooijen M., Habbema J.D. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009, 101(August (15)):1083-1092.